Research Article Details
| Article ID: | A16583 |
| PMID: | 28297798 |
| Source: | Zhonghua Gan Zang Bing Za Zhi |
| Title: | [Treatment of non-alcoholic fatty liver disease: an interpretation of the European clinical guidelines for obesity, type 2 diabetes, and digestive disease]. |
| Abstract: | Although many Chinese and international guidelines offer recommendations for the treatment of nonalcoholic fatty liver disease (NAFLD), there are also confusions in clinical practice, including the differences in drug indications, drug selection, the basic principles of lifestyle intervention, and key points in individual regimens between Chinese and international guidelines. In addition, there are also differences in many aspects including medical model and medical insurance system between the East and the West. These differences are great challenges for clinical practice, and the hepatologists in China have to face the challenges of localization when following the guidelines for the treatment of NAFLD. |
| DOI: | 10.3760/cma.j.issn.1007-3418.2017.02.008 |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D223 | Metabolic Cofactor Supplementation | Supplement | -- | -- | -- | Under clinical trials | Details |